Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial · scientific article published on 11 September 2018 · YYNN

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial

? TBD

scientific article published on 11 September 2018

Ratings
0

Nobody has rated this yet. Be the first!

Lists
0

Instance of

Scholarly article

Author

Paul G. Richardson

Subject

Multiple myeloma

Wikidata